Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE4
Enrollment 320
Locations 28 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Tumor Tissue and Blood Draw — Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.

Primary Outcomes

  • Changes from baseline in HER2 protein levels measured at the time of disease progression/recurrence (Cohorts H1 and H2) (At least 6 months)
  • Changes from baseline in HER2 gene copy number measured at the time of disease progression/recurrence (Cohorts H1 and H2) (At least 6 months)
  • Changes from baseline in estrogen receptor (ER) protein levels measured at the time of disease progression/recurrence (Cohorts H1 and H2) (At least 6 months)
  • Changes from baseline in HER2 protein levels measured at the time of disease progression/recurrence (Cohort H3) (Less than 6 months)
  • Changes from baseline in HER2 gene copy number measured at the time of disease progression/recurrence (Cohort H3) (Less than 6 months)
  • Changes from baseline in ER protein levels measured at the time of disease progression/recurrence (Cohort H3) (Less than 6 months)
  • Changes from baseline in genes related to CDK4/6 resistance (incl. cell cycle alterations and tyrosine kinase receptors, Cohort R1) (At least 6 months)
  • Changes from baseline in genes related to endocrine resistance (incl. cell cycle alterations and tyrosine kinase receptors, Cohort R1) (At least 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-04-02
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO44977 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Procedure: Tumor Tissue and Blood Draw — Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
Study Locations (28 sites)
Institut Jules Bordet, Anderlecht, 1070 Belgium
AZ KLINA, Brasschaat, 2930 Belgium
CHU de Liège (Sart Tilman), Liège, 4000 Belgium
AZ Delta (Campus Rumbeke), Roeselare, 8800 Belgium
Aalborg Universitetshospital, Aalborg, 9000 Denmark
Sjællands Universitetshospital, Næstved, Næstved, 4700 Denmark
Helsinki University Central Hospital, Helsinki, 00029 Finland
Tampere University Hospital, Tampere, 33520 Finland
St. Elisabeth Krankenhaus Köln GmbH, Cologne, 50935 Germany
KEM/Evang. Kliniken Essen Mitte gGmbH, Essen, 45136 Germany
Eligibility Criteria
General Inclusion Criteria: * Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw * Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment * Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred) * Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy * Discontinuation of prior anti-cancer treatment outlined below should not be longer than 4 weeks from participation in this study Inclusion criteria for participants in the cohorts studying acquired resistance * Participant had undergone regular monitoring for disease progression as per local practice (preferably every 3-6 months) while on most recent breast cancer therapy * Accessible tumor lesion that newly appeared or a lesion that started to regrow while the participant was at least 6 months on therapy Inclusion criteria for participants in the cohort studying primary resistance * Accessible tumor lesion that continued to increase in size or a newly appearing lesion (as confirmed by routine tumor assessment) while treated for at least 4 weeks but less than 6 months on therapy Exclusion Criteria: * Any risks factors that increase the risk of complications associated with the procedure to obtain tumor tissue (e.g. bleeding disorders) * Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study * Participant has started treatment with subsequent anti-cancer therapy * Participants whose progressive tumor lesion that is targeted for biopsy/resection is in the bone * Discontinuation of treatment was due to a reason other than disease progression
Conditions Anxiety and Depression
Phase PHASE2
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain. Since all these symptoms frequently occur together, they may have a common underlying biological basis. A single medication that could effectively treat all these symptoms would be ideal. Converging data suggest that pregnenolone is a promising pharmacological agent for treating multiple psychiatric symptoms and functional impairment. The investigators thus propose to conduct a clinical trial of pregnenolone in Veterans with anxiety and depression symptoms. Pregnenolone has minimal side effects, and the prior research demonstrates that pregnenolone is well-tolerated by Veterans. Treatment with pregnenolone could thus be an efficacious new therapeutic for Veterans experiencing depression, anxiety, poor sleep quality and chronic pain conditions.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Pregnenolone — Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
  • Drug: Placebo — Same as active comparator, except placebo dispensed

Primary Outcomes

  • The World Health Organization disability assessment schedule II (WHODAS-2) (Change from baseline at 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-14
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Jennifer C Naylor, PhD (PRINCIPAL_INVESTIGATOR) - Durham VA Medical Center, Durham, NC
  • Christine E. Marx, MD MA (PRINCIPAL_INVESTIGATOR) - Durham VA Medical Center, Durham, NC
Contact Information
Study Contact:
Jennifer C Naylor, PhD
(919) 286-0411
jennifer.naylor2@va.gov
Jennifer C Naylor, PhD
919-286-0411
jennifer.naylor2@va.gov
Durham VA Medical Center, Durham, NC
Christine E. Marx, MD MA
Durham VA Medical Center, Durham, NC
Interventions
  • Drug: Pregnenolone — Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
  • Drug: Placebo — Same as active comparator, except placebo dispensed
Study Locations (1 sites)
Durham VA Medical Center, Durham, NC, Durham, North Carolina 27705-3875 United States
Eligibility Criteria
Inclusion Criteria: * Veterans enrolled for care at the Durham VAHCS * Veterans who score a minimum score of 20 or higher (moderate symptoms) on the PHQ-ADS (Kroenke et al 2017) * Oral pregnenolone could reduce the effectiveness of oral contraceptives, thus women will be required to use a medically and study-approved contraceptive or otherwise not be of child-bearing potential. Birth control methods must be non-hormonal * No anticipated need to alter psychiatric medications for duration of study involvement * Ability to participate fully in the informed consent process Exclusion Criteria: * History of allergy to PREG * Medical disorders that may preclude safe administration of PREG or exacerbate mental or physical health symptoms * PTSD diagnosis, as per the PCL-5, scores of 38 or higher * Current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern * Prior attempts or suicidal ideation that does not require clinical intervention or represent an imminent concern is permitted * Serious unstable medical illness, such as history of cerebrovascular accident, prostate, uterine or breast cancer, others (at the discretion of the PI and medical oversight team) * Standard pharmacological interventions for mental health disorders will not be exclusionary; however, there may be no changes in psychotropic medications for mental or physical health conditions 4 weeks prior to study randomization * Benzodiazepine or opioid use * Current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than mild TBI (assessed at screening) * Initiation or change in psychotherapy within 3 months of randomization (i.e., psychotherapy must be stable for 3 months prior to study start * Due to lack of safety data in pregnant and breast-feeding women, female participants who are pregnant or breast-feeding will be excluded * As indicated by the DSM-5, moderate or severe Substance Use Disorders (excluding caffeine and tobacco) within 1 month of study entry
Conditions ER+ HER2- Advanced Breast Cancer, High-g...
Phase PHASE1, PHASE2
Enrollment 564
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AZD8421 — CDK2 inhibitor
  • Drug: Camizestrant — SERD
  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Palbociclib — CDK4/6 inhibitor
  • Drug: Abemaciclib — CDK4/6 inhibitor

Primary Outcomes

  • Incidence of dose limiting toxicities (DLTs) as defined in the protocol. (From start of treatment until the end of DLT period, assessed up to 28 days.)
  • Incidence of AEs/SAEs (From start of treatment until the end of safety follow-up, approximately 18 months.)
  • Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs. (From start of treatment until the end of safety follow-up, approximately 18 months.)
  • Discontinuation of AZD8421 due to toxicity (From start of treatment until the end of safety follow-up, approximately 18 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-12-05
Completion: 2027-08-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 564 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • Richard Baird, MD, PhD (STUDY_CHAIR) - Cambridge University Hospitals
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: AZD8421 — CDK2 inhibitor
  • Drug: Camizestrant — SERD
  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Palbociclib — CDK4/6 inhibitor
  • Drug: Abemaciclib — CDK4/6 inhibitor
Study Locations (14 sites)
Research Site, St Louis, Missouri 63141 United States
Research Site, Providence, Rhode Island 02903 United States
Research Site, Nashville, Tennessee 37201 United States
Research Site, Houston, Texas 77030 United States
Research Site, East Melbourne, 3002 Australia
Research Site, Seoul, 03722 South Korea
Research Site, Seoul, 06351 South Korea
Research Site, Barcelona, 8035 Spain
Research Site, Pamplona, 31005 Spain
Research Site, Valencia, 46010 Spain
Eligibility Criteria
Inclusion Criteria: * Female participants only, aged 18 or above * Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best option for their next treatment based on response to and/or tolerability of prior therapy. * Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP. * ECOG/WHO performance status 0 to 1, and a minimum life expectancy of 12 weeks. * At least one lesion that is measurable and/or non-measurable, as per RECIST v1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment. Exclusion Criteria: * Intervention with any of the following: * Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs for the treatment of advanced cancer from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is shorter) of the first dose of IMP (21 days for myelosuppressive therapies) other than GnRHa (eg, goserelin) and bone-stabilizing agents (eg, zoledronic acid, denosumab). * Any prescription or non-prescription drugs or other products, including herbal products, known to be moderate or strong inhibitors/inducers of CYP3A4/5 which cannot be discontinued prior to first dose of IMP and withheld throughout the study until 2 weeks after the last dose of study drug. * Drugs that have a known risk of Torsades de Pointes. * Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP. * Major surgical procedure or significant traumatic injury, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anesthesia during the study. * Any unresolved toxicities of Grade ≥ 2 from prior anti-cancer therapy (with the exception of alopecia). Participants with stable ≤ Grade 2 neuropathy are eligible. * Presence of life-threatening metastatic visceral disease, as judged by the Investigator, uncontrolled CNS metastatic disease. Participants with spinal cord compression and/or brain metastases may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off steroids for at least 4 weeks prior to start of IMP. * Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or eg, infection requiring IV antibiotic therapy, or active infection including hepatitis B, hepatitis C, and HIV (active viral infection is defined as requiring antiviral therapy; screening for chronic conditions is not required). * Any of the following cardiac criteria: * Mean resting QTcF \> 470 msec obtained from a triplicate ECG * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Participants with controlled atrial fibrillation can be enrolled. * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death at \< 40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease. * LVEF \< 50%, and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥ 2, cerebrovascular accident, or transient ischemic attack. * Uncontrolled hypertension. * Inadequate bone marrow reserve or organ function as demonstrated by relevant laboratory values: * Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of IMP(s). * History of hypersensitivity to active or inactive excipients of AZD8421 or drugs with a similar chemical structure or class to AZD8421. * Previous treatment with AZD8421 or with any CDK2-selective inhibitor, or protein kinase membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 1 (PKMYT1) inhibitor, or WEE1 inhibitor. * Currently pregnant (confirmed with positive pregnancy test), breast feeding, or planning to become pregnant. Participants of childbearing potential must agree to use one highly effective contraceptive measure.
Conditions Sleep, Anxiety, Depression, Pain
Phase PHASE2
Enrollment 185
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: fsCBD Cannabidiol — Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
  • Drug: Placebo — Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
  • Drug: bsCBD Cannabidiol — Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used

Primary Outcomes

  • Pain Interference (Baseline, 4 weeks, 8 weeks)
  • Pain Intensity (Baseline, 4 weeks, 8 weeks)
  • Pain Inventory (Baseline, 4 weeks, 8 weeks)
  • Sleep Disturbance (Baseline, 4 weeks, 8 weeks)
  • Sleep-Related Impairment (Baseline, 4 weeks, 8 weeks)
  • Depression/Anxiety (Baseline, 4 weeks, 8 weeks)
  • Fatigue (Baseline, 4 weeks, 8 weeks)
  • Health Related Quality of Life (Baseline, 4 weeks, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-16
Completion: 2028-06-30
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 185 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Boulder
Contact Information
Study Contact:
Kyle Chrystal, BA
603-769-7718
kyle.chrystal@colorado.edu
Harmony Soffer, BA
925-334-4031
harmony.soffer@colorado.edu
Anschutz Health Sciences Building
Interventions
  • Drug: fsCBD Cannabidiol — Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
  • Drug: Placebo — Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
  • Drug: bsCBD Cannabidiol — Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
Study Locations (1 sites)
Anschutz Health Sciences Building, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: 1. Able to provide informed consent 2. Aged ≥25 years at Visit 1 (Baseline) 3. Have a diagnosis of any solid tumor type and is currently undergoing or has undergone either curative or palliative treatment in the past 18 months 4. Currently experiencing symptoms of sleep problems, pain, and/or mood disturbance (i.e., depression, anxiety) 5. Desire to use cannabis to treat their symptoms 6. Must not have been regularly using any cannabis products (more than 3x/month) in the last 6 months 7. Willing to practice acceptable methods of birth control until completing study medication Exclusion Criteria: 1. Report of illegal drug use (e.g., cocaine, methamphetamine) in the past 90 days 2. Current use of anti-epileptic medications (e.g., clobazam, sodium valproate, lamotrigine) 3. Current use of medications known to have major interactions with Epidiolex (e.g., buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide) 4. Current use of anti-psychotic medications 5. Current use of potent CYP2C19 or CYP3A4 inducers (e.g., Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib9, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, Primidone) 6. Liver function tests (Alanine transaminase \[ALT\] and Aspartate transaminase \[AST\]) levels ≥2x the upper normal limits 7. Moderate or severe liver disease 8. Past or current diagnosis, or family history of diagnosis, of psychosis; current major psychiatric illness, such as bipolar disorder, major depression, or schizophrenia 9. History of seizures 10. For female participant of childbearing potential: Pregnant or lactating at the time of study enrollment or trying to become pregnant. Lack of childbearing potential confirmed by a history of amenorrhea for at least 12 consecutive months and serum FSH level within the laboratory's reference range for postmenopausal females OR documented bilateral oophorectomy and/or hysterectomy 11. Physician response to passive consent indicating contraindications for participation. 12. Unwilling to refrain from cannabis use other than study drug for the entire study duration 13. Men who consume more than 2 alcoholic beverages per day and women who consume more than 1 alcoholic beverage per day
Conditions Pediatric Asthma, Critical Illness
Phase PHASE2, PHASE3
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Azithromycin — 10mg/kg/dose (max dose 500mg) once daily for 3 days

Primary Outcomes

  • Plasma Periostin Levels and Degree of Change (e.g., Slope) - Primary Physiologic Efficacy Endpoint (24 hours, 48 hours, and 72-hours following enrollment)
  • Drug-related adverse event rate (Primary Safety Endpoint) (During hospitalization, approximately 3 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2024-04-02
Completion: 2027-06-30
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins All Children's Hospital
Principal Investigators:
  • Anthony A Sochet, MD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins All Children's Hospital
Contact Information
Study Contact:
Anthony A Sochet, MD
727-487-3711
Sochet@jhmi.edu
Alexa R Roberts, MD
602-526-4397
arober77@jhmi.edu
Anthony A Sochet, MD
727-767-2912
sochet@jhmi.edu
Johns Hopkins All Children's Hospital
Interventions
  • Drug: Azithromycin — 10mg/kg/dose (max dose 500mg) once daily for 3 days
Study Locations (1 sites)
Johns Hopkins All Children's Hospital, St. Petersburg, Florida 33701 United States
Eligibility Criteria
Inclusion criteria * Age 3-17 years * Admission to the PICU * Primary diagnosis of critical asthma * Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy * Prescription for intravenous systemic corticosteroids Exclusion criteria * Critical Congenital Heart Disease Unrepaired * Tracheostomy Dependence at Admission * Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication * Past Medical History of Prolonged QT Syndrome or Arrhythmias * Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Conditions Hypertension
Phase NA
Enrollment 1176
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 adults with hypertension (approximately 28 per church) from 42 predominantly Black churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline — The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Primary Outcomes

  • Difference in mean change of systolic blood pressure (Measured from baseline to 18 months)
  • Implementation fidelity summary score (Measured at 6, 12, and 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1176 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tulane University
Collaborators: National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Allison N Marshall, PhD MPH MSSW
5049886454
amarshall@tulane.edu
Tulane University
Jodie Laurent, MPH
504-988-5432
jlaurent@tulane.edu
Tulane University
Interventions
  • Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline — The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
Study Locations (1 sites)
Tulane University, New Orleans, Louisiana 70112 United States
Eligibility Criteria
Inclusion Criteria: 1. Men or women aged ≥18 years 2. Community members associated with the participating churches (church members and their families and friends) 3. Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg 4. Willing and able to participate in the intervention. 5. Willing and able to sign written informed consent. Exclusion Criteria: 1. Prior hospitalization in the last 3 months for chronic heart failure or heart attack 2. Current diagnosis of cancer requiring chemotherapy or radiation therapy 3. Stage-5 chronic kidney disease requiring chronic dialysis or transplant 4. Pregnant or planning to become pregnant in the next 18 months 5. Planning to move out of the Greater New Orleans area during the next year
Conditions Liver Cirrhosis, Hepatic Cell Carcinoma,...
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Injection of a gadolinium contrast agen — All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs). * About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent; * After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;
  • Drug: Radiotracer Injection — All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA; * The catheter will be flushed post-injection with 0.9% saline solution * The injected dose and the time of injection will be recorded. * The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan
  • Diagnostic Test: Imaging — PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.

Primary Outcomes

  • Assessment of LI-RADS with Ga-PSMA-PET/MRI (1-2 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-10
Completion: 2026-12-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Principal Investigators:
  • Onofrio Catalano (PRINCIPAL_INVESTIGATOR) - ocatalano@mgh.harvard.edu
Contact Information
Study Contact:
Onofrio Catalano, MD, Ph.D
617-724-4030
ocatalano@mgh.harvard.edu
Diandrea Galloway
617-643-1407
dgalloway@mgh.harvard.edu
Onforio Catalano, MD, Ph.D
617-724-4030
ocatalano@mgh.harvard.edu
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School
Interventions
  • Drug: Injection of a gadolinium contrast agen — All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs). * About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent; * After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;
  • Drug: Radiotracer Injection — All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA; * The catheter will be flushed post-injection with 0.9% saline solution * The injected dose and the time of injection will be recorded. * The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan
  • Diagnostic Test: Imaging — PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
Study Locations (1 sites)
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129 United States
Eligibility Criteria
Inclusion Criteria: * Liver cirrhosis as diagnosed by imaging and/or clinical data, including pathology Exclusion Criteria: * Any contraindication to PET, as in attached screening form * Any contraindication to MRI, as in attached screening form * Any contraindication to gadolinium-based contrast agent, including allergy to gadolinium, as in attached screening forms. * Pregnancy * Breast feeding. * Cumulative radiation exposure for research studies during the prior 12 months, combined with the exposure from this study, \> 50 mSv * Inability to fit in the scanner: weight \> 300 lbs or BMI \> 33
Conditions Breast Cancer Stage 0, Breast Cancer Sta...
Phase NA
Enrollment 800
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: CONSYDER decision aid — Web-based breast cancer surgery decision aid

Primary Outcomes

  • Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) (pre-surgery)
  • Use of CONSYDER pre-consult (pre-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-13
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Principal Investigators:
  • Shoshana Rosenberg, ScD, MPH (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
  • Rachel Greenup, MD, MPH (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Shoshana Rosenberg, ScD, MPH
646-962-8041
shr4009@med.cornell.edu
Darima Dorzhieva
646-962-8666
dad4011@med.cornell.edu
Rachel Greenup, MD, MPH
203-737-2966
rachel.greenup@yale.edu
Yale Cancer Center
Interventions
  • Other: CONSYDER decision aid — Web-based breast cancer surgery decision aid
Study Locations (4 sites)
Yale Cancer Center, New Haven, Connecticut 06510 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Weill Cornell Medicine, New York, New York 10065 United States
Duke Cancer Institute, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: * Female aged 18-44 * New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer * English or Spanish speaking Exclusion Criteria: * Diagnosis of de novo Stage 4 breast cancer * Recurrent early-stage breast cancer * Bilateral breast cancer
Conditions Hypertension, Resistant to Conventional ...
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Minocycline Hydrochloride — Minocycline Hydrochloride 100 mg twice daily
  • Drug: Placebo — Placebo

Primary Outcomes

  • 24-h systolic blood pressure (3 months)
  • Gut microbiome (3 months)
  • Gut inflammation and leakiness (3 months)
  • Neuroinflammation (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-08
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Collaborators: Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Steven M Smith, PharmD, MPH (PRINCIPAL_INVESTIGATOR) - University of Florida
Contact Information
Study Contact:
Joshua N Terrell
352-294-8297
jterrell5102@ufl.edu
David B Smith
352-294-8297
dbsmith@cop.ufl.edu
Joshua N Terrell
352-294-8297
jterrell5102@ufl.edu
UF Clinical Research Center (UF CRC) - CTSI
Interventions
  • Drug: Minocycline Hydrochloride — Minocycline Hydrochloride 100 mg twice daily
  • Drug: Placebo — Placebo
Study Locations (1 sites)
UF Clinical Research Center (UF CRC) - CTSI, Gainesville, Florida 32610 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic. * The participant agrees to have all study procedures performed Exclusion Criteria: * Known hypersensitivity or contraindication to minocycline or other tetracyclines * Recent (≤3 months prior), ongoing, or expected use of oral antibiotics * Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation * Known secondary hypertension * History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year * History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year * History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months * Evidence of alcoholism or drug abuse * Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS) * Current pregnancy or anticipated pregnancy during the study.
Conditions Postpartum Depression, Postpartum Anxiet...
Phase NA
Enrollment 384
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigator's long-term goal is to mitigate pregnancy-related mortality (PRM) risk by systematically delivering scalable integrated clinical and supportive care that is effective for all. The investigator's central hypothesis is that the Multi-modal Maternal Infant Perinatal Outpatient Delivery System (MOMI PODS) will mitigate postpartum (PP) risk for all by increasing patient engagement with evidence-based cilnical and supportive care, thus improving biopsychosocial profiles that drive clinical risk. To test this hypothesis, the investigators will conduct a hybrid type 1 randomized controlled trial (RCT) of MOMI PODS versus enhanced usual care (EUC, which we will term MOMI CARE) among a total sample of up to 384 mother-infant dyads (192/group) following pregnancy affected by a cardiometabolic and/or mental health condition. The investigators will enroll participants during late pregnancy and collect data at baseline and 6 months and 1 year PP. The investigators will collect implementation and service data across sites.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: MOMI PODS — MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
  • Behavioral: Enhanced Usual Care (EUC) — Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.

Primary Outcomes

  • Change in Life's Essential 8 (LE8) Composite Score (Baseline (T1) to 6 months postpartum (T2))
  • Change in Life's Essential 8 (LE8) Composite Score (6 months postpartum (T2) to 12 months postpartum (T3))
  • Change in Life's Essential 8 (LE8) Composite Score (Baseline (T1) to 12 months postpartum (T3))
  • Change in Patient Health Questionnaire-9 (PHQ-9) Score (Baseline (T1) to 6 months postpartum (T2))
  • Change in Patient Health Questionnaire-9 (PHQ-9) Score (6 months postpartum (T2) to 12 months postpartum (T3))
  • Change in Patient Health Questionnaire-9 (PHQ-9) Score (Baseline (T1) to 12 months postpartum (T3))
  • Change in Generalized Anxiety Disorder-7 (GAD-7) Score (Baseline (T1) to 6 months postpartum (T2))
  • Change in Generalized Anxiety Disorder-7 (GAD-7) Score (6 months postpartum (T2) to 12 months postpartum (T3))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-27
Completion: 2028-03-01
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Contact Information
Study Contact:
Shannon L. Gillespie, PhD, RN
6142924589
gillespie.175@osu.edu
Sandra Solove, MA
6142478366
solove.3@osu.edu
Shannon L. Gillespie, PhD, RN
6142924589
gillespie.175@osu.edu
The Ohio State University
Interventions
  • Behavioral: MOMI PODS — MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
  • Behavioral: Enhanced Usual Care (EUC) — Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
Study Locations (1 sites)
The Ohio State University, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: To be eligible for the MOMI PODS RCT, individuals will be required to be pregnant, with a current diagnosis or history of one or more of the following reflected in the medical record or by self-report - chronic hypertension (with or without super-imposed preeclampsia); gestational hypertension; preeclampsia; eclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; type 1 diabetes mellitus; type 2 diabetes mellitus; gestational diabetes mellitus (GDM); a depressive disorder (e.g., major depressive disorder, persistent depressive disorder) or anxiety disorder (e.g., generalized anxiety disorder, panic disorder).43-48 Inclusion criteria will also include a singleton pregnancy and medical record documentation or self-report of private or government-sponsored health insurance at the time of enrollment. Exclusion Criteria: Exclusion criteria will include the presence of a pre-existing, community driven MOMI PODS referral and enrollment into the program, maternal history of a seizure disorder, medical record documentation or self-report of a major complication of the infant that would be expected to preclude them from receiving or significantly delay their ability to receive outpatient pediatric care during the first year of life. Examples include but are not limited to anencephaly, myelomeningocele, esophageal atresia, gastroschisis, hypoplastic left heart syndrome, transposition of the great arteries, or tetralogy of Fallot. Exclusion criteria will also include the presence of a major genetic disorder among the infant that would be expected to preclude them from receiving or significantly delay their ability to receive outpatient pediatric care during the first year of life. Examples include but are not limited to trisomy 13, or trisomy 18 (trisomy 21 is not an exclusion criteria).
Conditions Triple Negative Breast Cancer (TNBC)
Phase PHASE2
Enrollment 40
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tenalisib — Tenalisib will be administered 800mg/ 400mg BID, orally

Primary Outcomes

  • Clinical Benefit Rate (CBR) (1 year)
  • Duration of Clinical Benefit (DoCB) (1 year)
  • Overall Response Rate (ORR) (1 year)
  • Progression Free Survival (PFS) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-04
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rhizen Pharmaceuticals SA
Collaborators: Incozen Therapeutics Pvt Ltd
Contact Information
Study Contact:
Prajak Barde, MD
+41325800175
pjb@rhizen.com
Dr. Priyadarshini Lakshmi
HCG City Cancer Center
Dr. Nidhi Tandon
Narayana Hrudayala Majumdar Shaw Hospital
Interventions
  • Drug: Tenalisib — Tenalisib will be administered 800mg/ 400mg BID, orally
Study Locations (9 sites)
HCG City Cancer Center, Vijayawada, Andhra Pradesh 520002 India
Narayana Hrudayala Majumdar Shaw Hospital, Bangalore, Karnataka 560099 India
Tata Memorial Centre, Mumbai, Maharashtra 400012 India
Mumbai Oncocare Centre, Mumbai, Maharashtra 400056 India
Sahyadri Super Speciality Hospital, Pune, Maharashtra 411004 India
Nobel Hospital, Pune, Maharashtra 411013 India
Meenakshi Mission Hospital & Research Center, Madurai, Tamil Nadu 625107 India
Nizams Institute of Medical Science, Hyderabad, Telangana 500082 India
Health Point Hospital, Kolkata, West Bengal 700025 India
Eligibility Criteria
Inclusion Criteria: 1. Patients who have histologically confirmed TNBC. 2. Patients who have received at least 1 but not more than 3 prior chemotherapy regimens in a metastatic setting. 3. Patients with at least one measurable lesion, per RECIST version 1.1 at baseline . Bone-only disease is not permitted. 4. ECOG performance status 0 to 2. 5. Adequate bone marrow, liver, and renal function Exclusion Criteria: 1. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter). 2. Patient who has not recovered from acute toxicities of previous therapy except treatment-related alopecia. 3. Prior exposure to PI3K inhibitors (e.g., alpelisib, buparlisib) for breast cancer. 4. Major surgery within 4 weeks of starting study treatment. 5. Patient with symptomatic uncontrolled brain metastasis. 6. Ongoing immunosuppressive therapy including systemic corticosteroids. 7. History of severe cutaneous reactions. 8. Concurrent disease or condition that would interfere with study participation 9. Pregnancy or lactation. 10. Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation
Conditions Pancreatic Adenocarcinoma, Cholangiocarc...
Phase PHASE2
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer that are resistant to Taxanes. Subjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment. If subject does not develop disease progression , the subject continues treatment until disease progression (RECIST 1.1) or develops an intolerable toxicity, initiation of a new anti-cancer drug, withdrawal from the study, death, or loss of follow-up. This is a single-arm, small-sample clinical study with the primary efficacy goal of objective remission rate (ORR). The parameters of the trial were set: assuming a class I error of 0.025 unilaterally, power=90%, and a 15% improvement in ORR for objective remission rate, a total of 20 subjects would be required, and a total of 25 would be required for enrolment, taking into account a 20% shedding.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel Polymeric Micelles for Injection — 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.

Primary Outcomes

  • Objective Response Rate (Baseline to measured PD(up to 24 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-28
Completion: 2025-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liu Huang
Principal Investigators:
  • Xianglin Yuan (PRINCIPAL_INVESTIGATOR) - Tongji Hospital
Contact Information
Study Contact:
Liu Huang
63639656
huangliu@tjh.tjmu.edu.cn
Liu Huang
63639656
huangliu@tjh.tjmu.edu.cn
Tongji Hospital
Interventions
  • Drug: Paclitaxel Polymeric Micelles for Injection — 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Study Locations (1 sites)
Tongji Hospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * 1.Male or female 18 years and older; 2.Patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer diagnosed by histological or cytological pathology; must have an evaluable lesion; 3.Previous treatment regimen includes Taxanes and is resistant to Taxanes (including patients with initial failure to remit or progression after remission) or previous use of Taxanes for at least 2 cycles without tumour shrinkage and the patient is not satisfied with current stable efficacy and is willing to be enrolled in this study; 4.ECOG (Eastern Cooperative Oncology Group) score ≤ 2 points; 5.expected survival of at least 3 months; 6.Blood routine examination meets the following criteria: 1. WBC≥3.0×109 /L,ANC≥1.5×109 /L; 2. PLT≥100×109 /L; 3. Hb≥80g/L; 7.Blood biochemical examination must meet the following criteria: <!-- --> 1. Total bilirubin ≤1.5 times the upper limit of normal (ULN); 2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) ≤2.5 times ULN (ALT, AST, or ALP≤ 5×ULN for subjects with liver metastases, and ALP≤10×ULN for subjects with bone metastases); 3. Creatinine clearance (calculated using Cockcroft-Gault formula) ≥50 ml/min; 8.Functions of major organs such as heart, lung, liver and kidney are basically normal; 9.Subjects have good compliance and voluntarily comply with the clinical trial protocol during the study, followed up by the investigators; 10.All women of childbearing age, men of childbearing potential, or their spouses who have no plans to have children or donate sperm during the entire trial period and up to 6 months after the last dose of medication, or who voluntarily used effective contraception; Women of childbearing age who have a negative blood/urine pregnancy test within 7 days prior to enrollment; 11.Subjects had fully understood the study and voluntarily signed the informed consent form . Exclusion Criteria: * 1.Subjects with an allergic history to experimental drugs or any excipients; 2.Subjects with acute or chronic infections that have not been eliminated, or subjects with other serious diseases at the same time; 3.Subjects with active hepatitis and uncontrolled by antiviral therapy, or liver metastasis is more than 3/4 of the whole liver; 4.Subjects with third-space effusions (e.g., moderate-to-massive pleural effusion, moderate-to-massive pericardial effusion, ascites) that cannot be controlled by drainage or other means; 5.Subjects with mental illness or disorder, poor compliance, or inability to cooperate, or describe treatment responses; 6.Subjects who cannot tolerate chemotherapy due to severe organic disease or major organ failure, such as decompensated heart and lung failure; 7.Subjects with bleeding disorders; 8.Subjects with organ transplant; 9.Subjects with bad drug addicts, long-term alcoholics, infectious diseases such as AIDS; 10.Subjects who still have grade ≥2 toxicity from previous antineoplastic therapy (except alopecia and grade ≤2 neurotoxicity caused by platinum) at enrollment; 11.Subjects are considered not able to complete the trial or otherwise unfit to participate in the study by the investigators.